Inhibition of Hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression

Molecular Cancer Research

Volumn 11, Issue 11, 2013, Pages 1448-1461

  Gowda, Pramod S ^a   Deng, Jianhong D ^a   Mishra, Sweta ^a   Bandyopadhyay, Abhik ^a   Liang, Sitai ^a   Lin, Shu ^a   Mahalingam, Devalingam ^a   Sun, Lu Zhe ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; CYCLOPAMINE; MESSENGER RNA; PROTEIN PATCHED; PYRVINIUM EMBONATE; SONIC HEDGEHOG PROTEIN; SONIDEGIB; TESTOSTERONE; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; VISMODEGIB;

ANCHORAGE INDEPENDENT GROWTH; ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL ACTIVITY; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROSTATE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL NUCLEUS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888223455     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0278     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Isaacs JT, Furuya Y, Berges R. The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol 1994;5:391-400.
3. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
4. Shamash J, Dancey G, Barlow C, Wilson P, Ansell W, Oliver RT. Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. Br J Cancer 2005;92:36-40.
5. Ruijter E, van de KC, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999;20:22-45.
6. Hyytinen ER, Thalmann GN, Zhau HE, Karhu R, Kallioniemi OP, Chung LW, et al. Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. Br J Cancer 1997;75:190-5.
7. Pilat MJ, Kamradt JM, Pienta KJ. Hormone resistance in prostate cancer. Cancer Metastasis Rev 1998;17:373-81.
8. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314-9.
9. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-6.
10. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-8.
11. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400.
12. Lamb DJ, Weigel NL, Marcelli M. Androgen receptors and their biology. Vitam Horm 2001;62:199-230.
13. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 1988;240:327-30.
14. Roy AK, Lavrovsky Y, Song CS, Chen S, Jung MH, Velu NK, et al. Regulation of androgen action. Vitam Horm 1999;55:309-52.
15. Tan JA, Joseph DR, Quarmby VE, Lubahn DB, Sar M, French FS, et al. The rat androgen receptor: primary structure, autoregulation of its messenger ribonucleic acid, and immunocytochemical localization of the receptor protein. Mol Endocrinol 1988;2:1276-85.
16. Tan J, Marschke KB, Ho KC, Perry ST, Wilson EM, French FS. Response elements of the androgen-regulated C3 gene. J Biol Chem 1992;267:7958.
17. Ho KC, Marschke KB, Tan J, Power SG, Wilson EM, French FS. A complex response element in intron 1 of the androgen-regulated 20-kDa protein gene displays cell type-dependent androgen receptor specificity. J Biol Chem 1993;268:27226-35.
18. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;167(2 Pt 2):948-51.
19. Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer 2011;18:R183-96.
20. Jones JO, Bolton EC, Huang Y, Feau C, Guy RK, Yamamoto KR, et al. Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci U S A 2009;106:7233-8.
21. Katoh Y, Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 2009;9:873-86.
22. Medina V, Calvo MB, az-Prado S, Espada J. Hedgehog signalling as a target in cancer stem cells. Clin Transl Oncol 2009;11:199-207.
23. Chen M, Tanner M, Levine AC, Levina E, Ohouo P, Buttyan R. Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells. Cell Cycle 2009;8:149-57.
24. Shaw G, Price AM, Ktori E, Bisson I, Purkis PE, McFaul S, et al. Hedgehog signalling in androgen independent prostate cancer. Eur Urol 2008;54:1333-43.
25. Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev 2008;22:2454-72.
26. Low JA, de Sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 2010;28:5321-6.
27. Merchant AA, Matsui W. Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010;16:3130-40.
28. Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 2006;66:6714-21.
29. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
30. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 2011;20:457-71.
31. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002;62:6606-14.
32. Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung HJ, Mudryj M. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 2007;67:9001-5.
33. Furr BJ, Tucker H. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 1996;47(A Suppl):13-25.
34. Sirab N, Terry S, Giton F, Caradec J, Chimingqi M, Moutereau S, et al. Androgens regulate Hedgehog signalling and proliferation in androgen-dependent prostate cells. Int J Cancer 2012;131:1297-306.
35. Lamont KR, Tindall DJ. Minireview: alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 2011;25:897-907.
36. Crawford ED, Petrylak D. Castration-resistant prostate cancer: descriptive yet pejorative? J Clin Oncol 2010;28:e408.
37. Brown RS, Edwards J, Dogan A, Payne H, Harland SJ, Bartlett JM, et al. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol 2002;198:237-44.
38. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89:552-6.
39. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994;54:2861-4.
40. Harada N, Inoue K, Yamaji R, Nakano Y, Inui H. Androgen deprivation causes truncation of the C-terminal region of androgen receptor in human prostate cancer LNCaP cells. Cancer Sci 2012;103:1022-7.
41. Marcias G, Erdmann E, Lapouge G, Siebert C, Barthelemy P, Duclos B, et al. Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Hum Mutat 2010;31:74-80.
42. Dehm SM, Tindall DJ. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem 2006;281:27882-93.
43. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004;431:707-12.
44. Sheng T, Li C, Zhang X, Chi S, He N, Chen K, et al. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer 2004;3:29.
45. Wang XD, Wang BE, Soriano R, Zha J, Zhang Z, Modrusan Z, et al. Expression profiling of the mouse prostate after castration and hormone replacement: implication of H-cadherin in prostate tumorigenesis. Differentiation 2007;75:219-34.
46. Chen M, Feuerstein MA, Levina E, Baghel PS, Carkner RD, Tanner MJ, et al. Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells. Mol Cancer 2010;9:89.